MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Explore this paper's citation graph
Summary
Direct evidence is provided that cholesterol-lowering therapy is beneficial for people with diabetes even if they do not already have manifest coronary disease or high cholesterol concentrations and statin therapy should now be considered routinely for all diabetic patients at sufficiently high risk of major vascular events, irrespective of their initial cholesterol concentrations.
- Type
- article
- Published
- 2003-06-14
- Cited by
- 2,870
- References
- 45
- OpenAlex
- https://openalex.org/W1502524639
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:28111189
Keywords
Medicine, Simvastatin, Diabetes mellitus, Myocardial infarction, Internal medicine
References
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
- Quantitative measurement of HbA1c by an immunoturbidimetric assay compared to a standard HPLC method.
- The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
- Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
- Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies.
- Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.
- Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
- Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
- Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
- Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
- Management of Dyslipidemia in Adults With Diabetes
- Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
- Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
- C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.
- Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort.
- Report of the Conference on Low Blood Cholesterol: Mortality Associations
Cited by
- Contemporary approaches for cardiovascular risk reduction in diabetes.
- Comments on the MRC/BHF Heart Protection Study.
- Bedeutung der Lipidtherapie bei Diabetes
- Evolving targets for risk reduction in diabetes
- Clinical Trials and Lipid Guidelines for Type II Diabetes
- Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients.
- LDL cholesterol and global risk stratification in referred hypertensive patients.
- Tight control of type 1 diabetes: recommendations for patients.
- Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
- Statins: another class of antihypertensive agents?
- Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
- Drugs and the fetus
- Diabetes guidelines: easier to preach than to practise?
- Expanding options with a wider range of rosuvastatin doses.
- Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain
- American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.
- Targets – who needs them? Success with statin therapies
- Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
- Diabetes mellitus and cerebrovascular disease: which are the actual data?
- Improvement of cardiovascular risk factors in patients with type 2 diabetes after long‐term continuous subcutaneous insulin infusion
Related papers
- The Effects of Simvastatin on Anti-Oxidation and Hypercholesterolemia in Rat
- Clinical beneficial effects of simvastatin on carotid atherosclerotic plaques in different doses
- Low dose simvastatin as maintenance treatment for hyperlipemia
- Study on patients with abnormal lipometabolism using simvastatin by two kinds of serum lipid adjusting methods
- 배추김치의 활성성분인 3 - (4 - hydroxyl - 3',5' - dimethoxyphenyl)propionic acid의 고지혈증 치료 효과
- Imported vs domestic simvastatin in treating primary hypercholestrolemia
- Simvastatin-loaded Liposome Nanoparticles Treatment for Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model: A Pilot Study
- 디클로로메탄과 초임계 이산화탄소의 혼합용매에서 Simvastatin 약물의 상거동과 초임계 역용매 공정을 이용한 Simvastatin 약물 미세입자의 제조
- Metabolic Fate of Simvastatin, an Inhibitor of HMG-CoA Reductase (1) : Absorption, Distribution, Metabolism and Excretion of [14C] Simvastatin after Single Administration in Male Rats